Developing strategies to overcome resistance to sunitinib is a major challenge in human renalcell carcinoma (RCC). Anti-angiogenic therapies act through hypoxia-induced tumor necrosis, but the mechanisms by which hypoxia induces treatment resistance in tumors remains unknown.
Introduction
Anti-angiogenic therapies have improved the prognosis of patients with metastatic renal-cell carcinoma (RCC), but secondary resistance constantly occurs (1) (2) (3) . These innovative therapies act through hypoxia-induced tumor necrosis (4), necrosis being considered an indirect marker of oxygen depletion (5) .
Preclinical data suggest a central role of hypoxia in the resistance to tyrosine-kinase-inhibitors such as sunitinib (6) (7) . Hypoxia induces resistance to chemotherapy in human cancer progenitors (8) (9) , and to targeted therapies in chronic myeloid leukemia cells (10) .
Hypoxia and necrosis occur in the spontaneous evolution of cancer. Hypoxia-inducible-factor-1α (HIF1α) stimulates angiogenesis by target gene activation (11) , and promotes endothelialcell progenitor and cancer stem-cell development (6, (12) (13) (14) . In tissues, where microenvironment conditions are thought to govern cancer stem-cells, little is known about the role of hypoxia.
According to consensus criteria, cancer stem-cells are able to self-renew and have tumorigenic potential (15) . Different surface markers characterize them, including CD133, expressed by hematopoietic stem-cells (16) , renal progenitors (17), brain (18) and colon cancer stem cells (19) , and CXCR4, expressed by human hematopoietic progenitors, renal progenitors (20) , and pancreatic cancer stem-cells (21) (22) .
Using CD133 and CXCR4 on human primary RCC biopsies and xenografted samples, we identified stem-cells around areas of spontaneous or sunitinib-induced necrosis. When these cells were sorted from xenografted human RCC before treatment, we demonstrated that hypoxia increased their tumorigenic potency, and decreased their sensitivity to sunitinib. Our results therefore strongly suggest that in human RCC sunitinib was able to generate resistance to its own therapeutic effect via induced hypoxia in peri-necrotic areas where cancer stem cells are found in increased numbers. 
Materials and Methods

Patients and RCC samples
Samples were obtained from primary tumors of seven patients with metastatic RCC, both before any medical treatment and after 3 months of sunitinib treatment (Pfizer, U.S.A.) at 50mg/day with a 4 weeks on and 2 weeks off schedule (1) , sunitinib being the first line of treatment. Imaging-guided pre-treatment biopsies were similarly performed at a minimum distance of 1 cm from necrotic areas detected on computed tomography, and processed as described in Supplementary methods. Table 1 shows tumor characteristics.
In compliance with French Bioethics-law (2004-800, 06/08/2004), all patients had been informed of the research use of the part of their samples remaining after diagnosis had been established, and did not oppose it. Informed consent was obtained for each patient. The study was approved by the University Board Ethics Committee.
Human RCC xenografts
Six xenograft models of human RCC in nude mice were studied (see Supplementary methods). The characteristics of the 6 xenografted human RCC models are shown in Table 2 .
The day when tumors reached a volume of 300 mm 3 -i.e. 100% tumor volume -was considered as Day0. Then, 15 of the 35 mice xenografted with human RCC were treated by gavage with sunitinib diluted in 0.9% NaCl, at 20mg/kg/day.
At Day21, when mice treated with sunitinib were compared with untreated mice, the xenograft model was considered as "responder" to sunitinib if tumor volumes were significantly smaller (p<0.01).
hypoxia and cancer stem-cells in renal cancer
For human primary RCCs before and after treatment with sunitinib, multiple-fluorescent immunostainings were performed (see Supplementary methods).
Assessment of necrosis area
Necrosis areas were assessed on tumor samples from all RCC xenograft models, at Day0, Day7, Day14 and Day21 (see Supplementary methods).
Cancer stem-cells from xenografted human RCC: spheres and tumorigenicity
We studied stem-cells from all RCC xenograft models. In the responder and non-responder models, we analysed the samples obtained at Day0, before any treatment. Cells obtained from dissociated sections were cultured as described in Supplementary methods, to obtain spheres.
We then assessed the tumorigenicity of CD133/CXCR4 co-expressing cells isolated from these spheres (see Supplementary methods).
Experimental hypoxia, assessment of proliferation and microvessel density
We studied spheres obtained from untreated tumor samples (Day0) from the six models.
These spheres were separated into two groups, maintained in a humidified chamber for seven days, one under experimental hypoxia (1% O 2 ) and the other under normoxia (20% O 2 ).
Assessment of proliferation and microvessel density was performed on tumor samples of xenografts obtained after engraftment of spheres cultured under normoxic or hypoxic conditions (see Supplementary methods).
Results
Stem-cells in perinecrotic areas
In the primary tumor samples of the 7 patients with metastatic RCC, before treatment and Figure 1A ).
In peri-necrotic areas in all patients, 84.5% (+/-2.5%) of these cells co-expressed CD133 and CXCR4, suggesting a stem-cell phenotype. These CD133/CXCR4-coexpressing cells were significantly more numerous in treated patients compared to untreated patients (7.3% versus 3.9% p<0.05). In addition, HIF1α, a marker of hypoxia, was co-expressed in 95% of CD133/CXCR4 cells ( Figure 1B ).
Six xenograft models of human RCC in nude mice were studied, obtained from engraftment of RCC primary tumor samples from patients with metastatic RCC. Each of the 6 xenograft models was treated with sunitinib for 21 days. A model was considered as "responder" to sunitinib treatment if its tumor volume at Day21 was significantly smaller than the mean tumor volume among untreated mice (p<0.01). When there was no significant difference in tumor volume between treated and untreated mice, the xenograft model was considered as non-responder to sunitinib treatment. Two of the 6 xenograft models were responder to sunitinib and the 4 others were non-responder models. In the two xenograft models responder to sunitinib (HRCC1 and HRCC8), a significant increase in necrotic areas was found between surface area for pooled results of these two models, p<0.05). In contrast, it took 21 days to observe necrotic areas both in the group of untreated mice (26.3 ±9.8%), and in the group of treated mice not responding to sunitinib (24.9% ±9.4) ( Figure 2B and Supplementary Figure   S1 ).
When we studied the six xenograft models, we again demonstrated that CD133-expressing cells were significantly more numerous in peri-necrotic than in peri-vascular areas, in both treated and untreated tumors. In addition, when we compared untreated and treated mice, CD133-expressing cells were significantly more numerous in treated mice, but only in perinecrotic areas (p<0.05) ( Figure 2C and Supplementary Figure S2 ).
These six pre-clinical models enabled us to perform in situ analyses on whole xenografted tumors. After removal of the whole tumor and realization of five representative full sections, the percentages of necrotic areas and of CD133 positive cells were assessed in the five different sections for each tumor ( Figure 2D ). When we studied untreated and treated mice together, including responders and non-responders to sunitinib (n=120 mice), the necrosis ratio in tumor tissue sections was significantly related to the mean number of CD133-expressing cells (p<0.01) ( Figure 2D ).
When we used pimonidazole, another hypoxic marker, we showed that hypoxic living cells stained for pimonidazole were distributed around necrotic areas. This was observed in the RCC xenograft models when necrosis occurred, at Day21 for one untreated RCC xenograft model, and at Day7 under treatment for one xenograft model that was responder to sunitinib (Supplementary Figure S3) ".
Since tissue necrosis is directly related to hypoxia, these results strongly suggest a link between hypoxia, whether sunitinib-induced or spontaneous, and an increased number of RCC stem-cells.
CD133/CXCR4 stem-cells had tumorigenic potential
Research. To determine if CD133/CXCR4 co-expressing cells were tumorigenic in vivo, we grew spheres from untreated RCC xenografts. When these spheres were cultured in normoxic conditions, confocal microscopy identified CD133/CXCR4 co-expressing cells ( Figure 3A ).
These cells isolated from normoxic spheres induced tumor growth 3 weeks after injection of 2.10 3 cells into nude mice. This tumorigenic potential was observed with CD133/CXCR4 coexpressing cells from normoxic spheres derived both from the two sunitinib responder models ( Figure 3B ) and the four non-responder models ( Figure 4A ).
As controls, 2.10 3 cells from the CD133/CXCR4 double-negative fraction of normoxic spheres injected in nude mice did not induce any tumor growth over a period of two months (Supplementary Table) . Microscope analyses and cell counts showed that tumors that developed from CD133/CXCR4 co-expressing cells reproduced the initial primary human RCC features for morphology, cell proliferation, microvessel density, and stem-cell density ( Figure 3B and 4A).
Experimental hypoxia increased stem-cell tumorigenicity
We compared the tumorigenic potential of spheres cultured under hypoxic and normoxic conditions. After injection of CD133/CXCR4 co-expressing cells sorted from spheres, there was a significantly larger mean tumor volume after injection of hypoxic stem-cells rather than normoxic stem-cells (p<0.05) ( Figure 3C and 4B). This difference was significant from 42 days on for the two responder models ( Figure 3C ) and for the four non-responder models ( Figure 4B ). To rule out a difference due to proliferation or angiogenesis, we counted Ki67-and CD31-expressing cells in tumor sections, and no significant difference was found in tumors grown from normoxic and hypoxic spheres ( Figure 3C ).
When we tested the tumorigenic potential of serial dilutions of isolated CD133/CXCR4 cells from normoxic and hypoxic spheres, a significant increase in tumor growth occurred after injection of 2.10 2 and 2.10 3 cells when hypoxic spheres were compared to normoxic spheres.
Research. The difference was not significant after injection of a larger number of cells (2.10 4 cells) ( Figure 3C and 4C).
Experimental hypoxia increased the number of stem-cells and decreased their sensitivity to sunitinib
To assess the role of experimental hypoxia on the number of renal cancer stem-cells, spheres derived from untreated tumors of the six human RCC xenograft models were cultured under hypoxic conditions.
After 5 days of experimental hypoxia, FACS analyses showed a significantly larger number of CD133/CXCR4 cells in hypoxic spheres compared to normoxic spheres (p<0.01). This was found in the two responder models (7.6% ± 2 versus 2.1% ± 0.7) (p<0.01) ( Figure 3D ), and the four non-responder models (9.2% ± 2.2 versus 4.6% ± 1.1) (p<0.01) ( Figure 4C ).
To assess sunitinib effects on RCC stem-cells, we then analysed whether CD133/CXCR4 cells from hypoxic spheres were more sunitinib-resistant than CD133/CXCR4 cells from normoxic spheres, using an in vitro cytotoxicity assay. The half-maximum-inhibitionconcentration (IC50) of sunitinib was higher for hypoxic than for normoxic cells for both the two responder models ( Figure 3D ), and the four non-responder models ( Figure 4D ).
Research. 
Discussion
In patients with metastatic RCC who were responders to sunitinib, we identified CD133/CXCR4-coexpressing stem-cells in peri-necrotic areas, and showed that their numbers increased after sunitinib administration. To our knowledge, this has never been reported in human RCC.
We chose CD133 and CXCR4 because they are two well-known markers of stem-cells (16) (17) (18) (19) (20) . In a series of 240 RCC, more than 20% positive cells were found for CD133-expressing cells in 22.5% of RCC, and for CXCR4-expressing cells in 60.8% of RCC (23), and high CXCR4 expression was predictive of poor response to sunitinib (24) . The seven patients we studied had at least a stable disease under sunitinib treatment (for this reason they underwent nephrectomy after treatment), and when we assessed the number of CD133/CXCR4 coexpressing cells, we found a mean percentage from 4.2% to 7.7%.
To further study these stem-cells, we xenografted human RCC in nude mice, and performed a sequential study in untreated and sunitinib-treated mice. We obtained 6 models, two of which were responders to sunitinib. Using these two responder models, we were able to reproduce the clinical and pathological results found in the seven patients, thus showing that sunitinib significantly increased the number of CD133/CXCR4 co-expressing stem-cells with a preferential peri-necrotic distribution. When all xenografted human RCC, whether treated or untreated, responders or non responders to sunitinib, were considered (i.e. 120 tumor samples), we demonstrated that the number of CD133/CXCR4 co-expressing cells was related to the extent of tissue necrosis. In a preclinical model of breast cancer cell lines (7), the number of cancer stem-cells increased under sunitinib via hypoxia. Here, we studied renal and not breast cancer, and human tumor samples and not cancer cell lines.
Regarding renal cancer stem-cells, CD105, more than CD133, has been recommended following studies using cells selected by flow cytometry (25). However, CD105 is not appropriate for studies in whole tumor tissue sections, because it is also expressed by tumor endothelial cells (26) and carcinoma-associated fibroblasts (27) .
In our preclinical model of human RCC xenografts, the number of stem-cells, preferentially distributed in peri-necrotic areas, was related to the extent of tissue necrosis, whatever the origin of necrosis, spontaneous or treatment-induced. In patients with metastatic RCC, resistance to anti-angiogenic treatment is a major cause of poor survival (2-3) . In preclinical studies, it has been shown that resistance to sunitinib occurred because cancer cells acquired metastatic potential (33) (34) , and that sunitinib mainly acts by vascular effect and induction of necrosis (4). Our demonstration that hypoxia increases the number of cancer stem-cells while decreasing their sensitivity to sunitinib implies that the drug, by way of its initial effect on the tumor microvessels, is able to induce mechanisms of resistance to its own effect. This is coherent with the clinical observation showing that the benefit of sunitinib is only transitory (2).
VHL-gene
Designing new strategies to optimize anti-angiogenic therapies needs to take into account the deleterious effect of therapy-induced hypoxia, which, as shown in this study, is responsible The clinical relevance of our results is a major strength of this work, as resistance to antiangiogenic drugs is challenging daily practice in oncology. In addition, this study is to our knowledge the first to be performed on human RCC samples before and after treatment, the relevant results being reproduced in xenograft models responding to sunitinib treatment, thus generalizing the conclusions obtained in the patient samples.
